Gefitinib-Sensitizing Mutations in Esophageal Carcinoma
- 18 May 2006
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 354 (20), 2193-2194
- https://doi.org/10.1056/nejmc052698
Abstract
The sensitivity of lung cancer to gefitinib has been found to be associated with mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR),1-3 yet similar observations are not available for other solid tumors.4 We investigated whether gefitinib-sensitizing mutations in the EGFR gene were present in human esophageal tumors.Keywords
This publication has 5 references indexed in Scilit:
- Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutantsOncogene, 2005
- Lack of Mutations inEGFRin Gastroenteropancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2005
- Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung CancerClinical Cancer Research, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004